Today on Pharmaceutical Processing
MIT researchers think they’ve found a way to get more particles through a syringe
Stevanato Group lauches modular, robotic pharma inspection system with AI
Regulatory See More >
U.S. paying Novavax $1.6b to ramp up COVID-19 vaccine manufacturing
The U.S. Health and Human Services Dept. and Defense Dept. announced a joint agreement with Novavax (NSDQ:NVAX) worth $1.6 billion to scale the manufacturing of its COVID-19 vaccine candidate. Gaithersburg, Md.-based Novavax’s commercial-scale manufacturing is expected to produce 100 million doses of the investigational vaccine that would become available for use in clinical trials or,…
Facility See More >
Moderna, Catalent partner on COVID-19 vaccine candidate manufacturing
Moderna (NSDQ:MRNA) and Catalent (NYSE:CTLT) today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at Catalent’s biologics facility in Bloomington, Ind. Catalent will provide vial filling and packaging capacity, as well as additional staffing required for 24×7 manufacturing operations at the site to support production of an initial 100 million…
Supply Chain See More >
U.S. investing $42m to boost BD syringe and needle production
HHS’s Biomedical Advanced Research and Development Authority is helping BD expand operations and manufacturing capacity in Nebraska to boost syringe and needle supplies for an eventual COVID-19 vaccine. Becton Dickinson (NYSE:BDX) said today that the total project will cost $70 million, with BARDA providing $42 million. The company expects the new capacity to be online within…
J&J to pay Emergent BioSolutions an initial $480m to make COVID-19 vaccine
U.S. paying Novavax $1.6b to ramp up COVID-19 vaccine manufacturing
DOD launches $100m initiative to return COVID-19-related medtech, pharma manufacturing to the U.S.
Sherlock Biosciences announces manufacturing partnership for CRISPR-based COVID-19 test
Recalls See More >
Torrent Pharmaceuticals Issues Voluntary Nationwide Recall of Losartan Potassium Tablets
Torrent Pharmaceuticals Limited is voluntarily recalling two lots of Losartan potassium tablets, USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. The impurity detected in the API is N-nitrosodiethylamine (NDEA), which is a substance that occurs…
